Madrigal Pharmaceuticals (MDGL) Interest Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Interest Expenses data on file, last reported at $7.8 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 137.15% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $140.4 million, a 24964.29% increase from a year earlier, with the FY2025 full-year figure at $591.0 million, up 16.16% from the prior year.
• Interest Expenses for Q1 2026 stood at $7.8 million, down from $121.8 million in the prior quarter.
• Over the last five years, Interest Expenses for MDGL reached as high as $121.8 million in Q4 2025 and fell as low as -$10.1 million in Q4 2024.
• Historically, Interest Expenses has averaged $10.1 million across 5 years, with a median of $3.4 million in 2023.
• Across the five-year window, Interest Expenses slumped 353.64% in 2024 and jumped 1309.55% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $1.7 million in 2022, then soared by 136.09% to $4.0 million in 2023, then slumped by 353.64% to -$10.1 million in 2024, then soared by 1309.55% to $121.8 million in 2025, then plunged by 93.58% to $7.8 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $7.8 million in Q1 2026, $121.8 million in Q4 2025, and $7.5 million in Q3 2025.